Aclaris Therapeutics Inc (NASDAQ:ACRS) has received an average rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $41.25.
A number of equities research analysts have recently weighed in on ACRS shares. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Tuesday, October 10th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 4th. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. JMP Securities reissued an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th.
Aclaris Therapeutics (ACRS) traded up $0.02 on Monday, hitting $22.83. The stock had a trading volume of 332,800 shares, compared to its average volume of 293,721. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25. The stock has a market cap of $685.42 and a P/E ratio of -10.57.
Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at approximately $142,000. Point72 Asset Management L.P. increased its position in Aclaris Therapeutics by 3.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock worth $23,030,000 after buying an additional 29,896 shares during the period. Highbridge Capital Management LLC bought a new position in Aclaris Therapeutics in the 3rd quarter worth approximately $2,581,000. Alyeska Investment Group L.P. increased its position in Aclaris Therapeutics by 85.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock worth $12,076,000 after buying an additional 215,201 shares during the period. Finally, Boothbay Fund Management LLC increased its position in Aclaris Therapeutics by 60.3% in the 3rd quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock worth $535,000 after buying an additional 7,791 shares during the period. 92.02% of the stock is currently owned by institutional investors and hedge funds.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.